Navigation Links
AIDS Drugs Don't Need Routine Lab Monitoring
Date:12/9/2009

Finding is good news for first-line treatment in Africa, researchers say

WEDNESDAY, Dec. 9 (HealthDay News) -- In a finding that has implications for how the AIDS virus is treated in Africa, new research suggests that antiretroviral drugs can be given without routine monitoring by lab tests.

But tests of immune-system function might still be a good idea to monitor the progression of the disease and guide the second year of treatment, the study authors report.

Patients with HIV, the virus that causes AIDS, often receive drug treatment in Africa without routine laboratory monitoring. In the study, published online Tuesday in advance of publication in a future print issue of The Lancet, researchers tried to determine if that's a bad idea.

They studied 3,316 HIV-positive adults who were assigned to monitoring in both the doctor's office and the laboratory or only in the doctor's office. The patients were studied in Uganda and Zimbabwe.

"The results clearly show that first-line [antiretroviral therapy, or ART] can be delivered safely without routine biochemistry and hematology monitoring for toxic effects, but that routine CD4-cell count monitoring has a small but significant benefit in terms of disease progression and mortality, probably owing to slightly earlier switching to second-line ART," the researchers wrote.

More information

Avert has more about AIDS in Africa.



-- Randy Dotinga



SOURCE: The Lancet, news release, Dec. 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Statement of HDMA President and CEO John M. Gray on the Importation of Prescription Drugs
2. Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs
3. OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable
4. Second-line CML drugs evoke faster response than front-line therapy
5. Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
6. Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
7. Diabetes Drugs Go Head-to-Head in Study
8. drugstore.com Continues Global Sales Expansion to More Than 3.5 Billion International Consumers
9. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
10. Coverage of inexpensive drugs may increase length and quality of life after heart attack
11. Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding ... The following programs will be expanding due to high demand: Master of Business Administration ... will begin this summer. , School of Business Graduate Program Chair Dr. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study ... severe congenital diaphragmatic hernia have better survival rates if surgery is performed early. ... condition where the diaphragm fails to form completely, letting abdominal organs into the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... patented products, announces the Gyrociser, an exercise invention which aids in proper muscle ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
Breaking Medicine Technology: